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Abstract The Chromogranin A (CgA)-derived anti-
hypertensive peptide catestatin (CST) antagonizes cate-
cholamine secretion, and is a negative myocardial inotrope
acting via a nitric oxide-dependent mechanism. It is not
known whether CST contributes to ischemia/reperfusion
injury or is a component of a cardioprotective response to
limit injury. Here, we tested whether CST by virtue of its
negative inotropic activity improves post-ischemic cardiac
function and cardiomyocyte survival. Three groups of
isolated perfused hearts from adult Wistar rats underwent
30-min ischemia and 120-min reperfusion (I/R, Group 1),
or were post-conditioned by brief ischemic episodes
(PostC, 5-cycles of 10-s I/R at the beginning of 120-min
reperfusion, Group 2), or with exogenous CST (75 nM for
20 min, CST-Post, Group-3) at the onset of reperfusion.
Perfusion pressure and left ventricular pressure (LVP) were
monitored. Infarct size was evaluated with nitroblue-tet-
razolium staining. The CST (5 nM) effects were also tested
in simulated ischemia/reperfusion experiments on cardio-
myocytes isolated from young-adult rats, evaluating cell
survival with propidium iodide labeling. Infarct size was
61 ± 6% of risk area in hearts subjected to I/R only. PostC
reduced infarct size to 34 ± 5%. Infarct size in CST-Post
was 36 ± 3% of risk area (P\0.05 respect to I/R).
CST-Post reduced post-ischemic rise of diastolic LVP, an
index of contracture, and signiﬁcantly improved post-
ischemic recovery of developed LVP. In isolated cardio-
myocytes, CST increased the cell viability rate by about
65% after simulated ischemia/reperfusion. These results
suggest a novel cardioprotective role for CST, which
appears mainly due to a direct reduction of post-ischemic
myocardial damages and dysfunction, rather than to an
involvement of adrenergic terminals and/or endothelium.
Keywords Chromogranin A  Cardioprotection 
Ischemia  Post-conditioning  Reperfusion injury
Introduction
Chromogranin A (CgA), a 48-kDa acidic secretory protein,
is highly conserved in the vertebrate secretory granules of
both the diffuse neuroendocrine system (Helle et al. 2007,
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it is co-stored and co-secreted with catecholamines and
natriuretic peptides. CgA plasma levels have long been used
for clinical applications as a biomarker of neuroendocrine
tumors (O’Connor et al. 2008). Recently, CgA has emerged
as a marker of cardiovascular dysfunctions, such as essen-
tial hypertension (Mahapatra et al. 2005; Rao et al. 2007;
Jansson et al. 2009), hypertrophic/dilatative cardiomyopa-
thy, and heart failure (Ceconi et al. 2002; Pieroni et al.
2007). Of note, in acute coronary syndromes, circulating
levels of CgA provide prognostic information indepen-
dently from conventional risk markers, predictinglong-term
mortality and heart failure hospitalizations during follow-up
(Jansson et al. 2009). Moreover, increased plasma levels of
CgA are present in patients after myocardial infarction
(Omland et al. 2003). In a recent study, though the circu-
lating CgA levels are associated with several established
risk markers in chronic heart failure (CHF) patients,
including increased age, diabetes, reduced renal function,
and heart rate variability, the CgA levels did not provide
incremental prognostic information to that obtained from
other established parameters (Rosjo et al. 2010).
The involvement of CgA in cardiovascular homeostasis
is also strongly supported by its function as a prohormone.
Via post-translational proteolytic processing, it gives rise to
bioactive peptides implicated in various counter-regulatory
processes (Helle et al. 2007, Helle 2010). Recently, we
showed that the N-terminal CgA-derived Vasostatin 1
(VS-1; human recombinant CgA1–78) protects against the
extension of myocardial infarction in the rat, inducing a
pre-conditioning-like effect via adenosine/nitric oxide
(NO) signaling if administered at low concentration before
ischemia/reperfusion (I/R) (Cappello et al. 2007). VS-1 is
also able to counteract the effects of adrenergic stimulation
(Cerra et al. 2006) via an endothelial and endocardial
release of nitric oxide, thus contributing to protection
against excessive excitatory sympathetic challenges (Gallo
et al. 2007; Cerra et al. 2008).
Among the other CgA-derived peptides, catestatin
(CST, hCgA352–372) is known to exert several in vivo and
in vitro cardiovascular activities. It is an endogenous non-
competitive antagonist of nicotine-evoked catecholamine
secretion (O’Connor and Deftos 1986; O’Connor et al.
2002; Mahata et al. 1997, 2000, 2004; Herrero et al. 2002;
Mahapatra et al. 2005; Mahata et al. 2010), which induces
vasodilatation through both inhibition of catecholamine
release and increased circulating levels of histamine
(Kennedy et al. 1998). Recent studies indicate that CST
also caused vasodilation in human subjects (Fung et al.
2010). CST plasma levels are decreased not only in
hypertensive patients but also in their still-normotensive
offsprings (O’Connor et al. 2002). Consistent with
these human studies, exogenous CST rescues arterial
hypertension of CgA knockout mice (Mahapatra et al.
2005). Recently, on the isolated rat heart, CST was found
to elicit, similarly to VS-1, negative inotropic and lusi-
tropic actions, as well as a vasorelaxant inﬂuence on cor-
onary arteries pre-contracted by either isoproterenol or
endothelin-1 (Cerra et al. 2006; Angelone et al. 2008).
Recently, it has been shown that CST replacement
improves dampened baroreﬂex sensitivity (Gayen et al.
2009) and heart rate variability (Dev et al. 2010) in CgA
knockout mice. Taken together, these data point to CST as
a novel regulator of cardiac function and blood pressure
(Mahata et al. 2010; Helle 2010).
On the basis of these cardiovascular effects of CST, the
possibility exists that this CgA-derived peptide exerts
cardioprotective inﬂuence under I/R conditions. Indeed,
cardioprotection includes endothelial and adrenergic com-
ponents (Bell and Yellon 2003; Pagliaro et al. 2003;
Cappello et al. 2007; Heusch et al. 2008), which are known
to be affected by CST (via anti-endothelin-1/pro-nitric
oxide and anti-adrenergic actions, respectively (Mahata
et al. 2000; Herrero et al. 2002; Angelone et al. 2008). This
provides a rationale for the hypothesis that CST may
inﬂuence the cardioprotective response. Since the role of
CST in this aspect is yet to be addressed, in this study, we
aimed to explore the CST involvement in cardioprotection,
using both Langendorff reperfused rat heart and isolated
cardiomyocytes. In particular, we tested whether CST,
applied after an infarcting ischemia, could improve
recovery of post-ischemic cardiac function, limiting infarct
size in isolated heart. For comparative purpose, we also
studied ischemic post-conditioning (PostC), which is a
well-known protective procedure (Couvreur et al. 2006;
Penna et al. 2006, 2008a, b, 2009a, b, c; Hausenloy et al.
2009). To exclude a role for the endothelial and neural
effects, we also tested whether CST may limit cell death in
a model of isolated cardiomyocytes exposed to simulated
ischemia/reperfusion.
Materials and Methods
Animals
Male Wistar rats were used in accordance with Italian law
(DL-116, January 27, 1992) and the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
Isolated Heart Perfusion
The methods were similar to those previously described
(Penna et al. 2006, 2008b, c, 2009a, b, c). In brief, excised
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123hearts were paced and constant-ﬂow perfused with Krebs
solution. Hearts were then subjected to 30-min zero-ﬂow
global ischemia, followed by 120-min reperfusion (Group
1, I/R). In a second group, hearts underwent a protocol of
PostC (i.e., ﬁve cycles of 10-s reperfusion and ischemia
(Penna et al. 2006, 2008b, 2009a, b, c). In Group 3
(CST-Post group, n = 7) in lieu of PostC, CST (75 nM)
was infused for 20 min at the beginning of reperfusion
(Fig. 1a). The concentration of CST was chosen on the
basis of a preliminary dose–response curve (from 33 to
100 nM) as the dose that induced the highest infarct size
reduction (data not shown).
Left ventricular pressure (LVP) was monitored
throughout the experiments and infarct size was deter-
mined at the end of reperfusion.
Simulated Ischemia/Reperfusion on Isolated Adult Rat
Cardiomyocytes
Isolated cardiomyocytes were obtained from the hearts of
adult rats (n = 7, 200–300 g body wt) according to the
previouslydescribedmethod(Galloetal.2007).Preliminary
experiments were performed to determine the optimal con-
ditions for simulating I/R. Ischemic HEPES buffer is
described in ‘‘Solutions and drugs’’. In the simulated I/R
protocol (IB), cardiomyocytes were ﬁrst superfused with
oxygenated Tyrode solution for 5 min, followed by 15 min
ofischemicbuffer,and5 minofTyrode(reperfusion).Inthe
control protocol (Ctrl), cardiomyocytes were superfused/
reperfused with Tyrode for a total of 30 min. In the
IB ? CST protocol, cardiomyocytes were superfused with
Tyrode ? 5 nM CST for 5 min, ischemic buffer ? 5n M
CST for 15 min, and Tyrode alone for 5 min (Fig. 1b).
Cellular viability was evaluated by propidium iodide
(PI, 10 lg/ml) labeling. Images were acquired using a laser
scanning confocal system (Fluoview 200, Olympus Amer-
ica, Melville, NY) with an Ar/Kr laser (488 and 568 nm)
mountedonaninvertedmicroscope (modelIX70,Olympus)
equipped with a 920 UplanApo (NA 0.90). Confocal image
acquisitions for each experimental condition were per-
formed at the times I, II, and III indicated in Fig. 1b.
Solutions and Drugs
Tyrode control solution contained (mM): 154 NaCl, 4 KCl,
2 CaCl2, 1 MgCl2, 5.5 D-glucose, 5 HEPES, pH 7.4 adjusted
with NaOH. The Ca
2?-free Tyrode solution used in cell
isolation was the control Tyrode without CaCl2 and with
10-mM butanedionemonoxime (BDM, Sigma), pH adjusted
with NaOH. Isolated cardiomyocytes were cultured in
M1018 medium (Sigma), 1% FBS, 100-U/ml penicillin,
100-mg/ml streptomycin, 1:1,000 insulin–transferrin–sele-
nium (ITS, Sigma), 10-mM BDM. Ischemic buffer used for
I/R experiments contained (mM) 137 NaCl, 3.5 KCl, 0.88
CaCl2, 0.51 MgSO4, 5.5 D-glucose, 4 HEPES, 10 2-deoxy-
D-glucose, and 20 DL-lactic acid (pH 6.5).
Statistical Analysis
All data are expressed as means ± SEM. One-way
ANOVA and Newman–Keuls multiple comparison test (for
post-ANOVA comparisons) have been used to compare
infarct size; one-way ANOVA with the use of SNK test for
post hoc analysis have been used to compare cellular via-
bility. Functional data were compared with repeated mea-
sures ANOVA (time/group). A t test with Bonferroni
correction was also used to compare the last-time points of
functional data. Differences with P\0.05 were regarded
as statistically signiﬁcant.
Fig. 1 Experimental design: a Isolated, Langendorff-perfused
hearts. Hearts were stabilized for 40 min, and then subjected to
30 min of normothermic global ischemia followed by 120 min of
reperfusion. Post-conditioning (PostC) protocol (5 cycles 10-s
ischemia/reperfusion) is indicated by vertical lines at the beginning
of reperfusion period. CST-Post group received Catestatin (CST,
75 nM) during the initial 20-min reperfusion. b Isolated cardiomyo-
cytes. Tyrode group: cardiomyocytes were superfused/reperfused
with Tyrode for 30 min. Ischemic buffer group: superfusion with
Tyrode solution for 5 min, ischemic buffer for 15 min, and Tyrode
(reperfusion) for 5 min. Ischemic buffer ? CST group: superfusion
with Tyrode ? 5 nM CST for 5 min, ischemic buffer ? 5 nM CST
for 15 min and Tyrode alone for 5 min (reperfusion). The cellular
viability was evaluated by propidium iodide (PI, 10 lg/ml) labeling.
The points I, II, and III indicated by the arrows correspond to the
times of image acquisition for each experimental condition (for
further explanation see text)
Cell Mol Neurobiol (2010) 30:1171–1179 1173
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Isolated Hearts
Infarct Size
The risk area, i.e., left ventricular (LV) mass, was similar
in all groups (LV weight was 927 ± 14; range
559–1105 mg). Total infarct size (Fig. 2), expressed as a
percentage of LV mass was 61 ± 5 in I/R (Group 1). PostC
(Group 2) signiﬁcantly reduced the infarct size to 34 ± 5
(P\0.01 with respect to I/R). The infusion of CST
(75 nM) during early 20-min reperfusion reduced infarct
size to 42 ± 4% of LV mass (P\0.01 with respect to the
control, NS with respect to PostC).
Cardiac Functional Parameters
Baseline values of the considered parameters are reported
in Table 1.
Systolic Function
In Fig. 3a and b, developed LVP (dLVP) and maximum
rate of increase of LVP during systole (dP/dtmax) are
reported as percent variation with respect to baseline level.
The hearts of the I/R group present a marked limitation of
dLVP recovery; in fact at the end of reperfusion dLVP was
34 ± 10% of baseline level (P\0.001). PostC and CST-
Post signiﬁcantly improved the dLVP recovery during
reperfusion (P\0.05 with respect to I/R group, for both).
Actually, the improvement observed after CST was sig-
niﬁcantly higher (P\0.05) than that observed in PostC
group. In particular, at the end of reperfusion the recovery
was 52 ± 10% (P\0.05) and 63 ± 23% (P\0.05) of
baseline levels for PostC and CST-Post, respectively
(Fig. 3a). A similar trend was observed for dP/dtmax
recovery during reperfusion in the three groups, though
statistic differences were observed with respect to I/R
group only, and not between PostC and CST-Post (Fig. 3b).
Diastolic Function
Diastolic function is represented by the level of end-dia-
stolic LVP (LVEDP) and maximum rate of decrease of
LVP during diastole (dP/dtmin) during ischemia and
reperfusion (Fig. 3c, d). Contracture can be deﬁned as an
increase in LVEDP of 4 mmHg above the baseline level
(Baker et al. 2000; Pagliaro et al. 2003). I/R markedly
increased contracture. During reperfusion both PostC and
CST-Post signiﬁcantly limited contracture development
(Fig. 3c); in fact LVEDP at the end of reperfusion was
22 ± 7 and 35 ± 7 mmHg in PostC and CST-Post,
respectively (P\0.01 with respect to I/R for both).
Accordingly, dP/dtmin recovery during reperfusion was
signiﬁcantly improved by both PostC and CST (Fig. 3d).
Isolated Adult Rat Cardiomyocytes
The protective role of CST was also investigated on iso-
lated adult cardiomyocytes subjected to simulated I/R, as
indicated in the ‘‘Methods’’ (Fig. 1b). Image acquisitions
for each experimental condition (Ctrl, IB, or IB ? CST)
were performed at the times I, II, and III, showed in
Fig. 1b. Representative experiments are presented in
Fig. 4a. With respect to control (Ctrl), the appearance of
propidium iodide staining at the end of reperfusion (III) in
the ischemic (IB) sample clearly demonstrates the effec-
tiveness of I/R simulation. CST (5 nM) administration
(IB ? CST) signiﬁcantly (P\0.05, Fig. 4b) preserved
cell viability after reperfusion, being comparable to that
observed in control condition. Figure 4b summarizes
the results of these experiments: viability rate was
81.3 ± 10.8% in control, 12.9 ± 8.3% in IB, and 63.5 ±
17.0% in IB ? CST.
Discussion
CST (hCgA352–372; bCgA344–364), proteolytically processed
from CgA, is the most potent endogenous antagonist of
nicotinic-cholinergic receptor that inhibits nicotine-evoked
catecholamine secretion in an autocrine/paracrine fashion
(Mahata et al. 1997; 2010). It acts also as an anti-endo-
thelin-1 and pro-nitric oxide agent ex vivo (Angelone et al.
2008) and as a potent vasodilator in vivo (Kennedy et al.
1998), mainly through stimulation of histamine release, as
Fig. 2 Infarct size: the amount of necrotic tissue is expressed as
percent of the left ventricle (IS/LV), which is considered the risk area.
** P\0.01 with respect to I/R. ns not signiﬁcant (for further
explanation see text)
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et al. 2004). These ﬁndings, together with its suggested
implication as an endogenous anti-hypertensive regulator
(Mahapatra et al. 2005; Rao et al. 2007), point to CST as a
novel cardiac modulator to protect the heart against
excessive sympatho-chromafﬁn over-activation that could
signiﬁcantly inﬂuence the onset and the course of patho-
physiological conditions.
We have shown that in isolated rat hearts CST, given at
reperfusion (CST-Post), decreased the infarct size, limited
contracture and improved the post-ischemic systolic func-
tion. Furthermore, CST was found to be protective in a
Table 1 Hemodynamic parameters before ischemia
Group CPP (mmHg) dLVP (mmHg) dP/dtmax (mmHg/s) dP/dtmin (mmHg/s) LVEDP (mmHg)
Control 84 ± 48 1 ± 4 1890 ± 120 -1460 ± 105 5 ± 1
Post-conditioning 82 ± 38 3 ± 4 1935 ± 125 -1495 ± 109 4 ± 1
Catestatin-Post 81 ± 48 2 ± 4 1895 ± 90 -1480 ± 95 5 ± 1
CPP coronary perfusion pressure, dLVP developed left ventricular pressure, dP/dtmax maximum rate of increase of LVP during systole, dP/dtmin
maximum rate of decrease of LVP during diastole, LVEDP left ventricular end diastolic pressure
Fig. 3 Systolic function: a Percent variation of developed LVP
(dLVP) with respect to baseline level for each group, during the
30-min ischemia and 120-min reperfusion. b Percent variation of ﬁrst
derivative of LVP during systole (dP/dtmax) with respect to baseline
level for each group, during the 30-min ischemia and 120-min
reperfusion. Time 0 correspond to the beginning of reperfusion. PostC
post-conditioning, CST catestatin. * P\0.05 with respect to I/R;
# P\0.05 with respect to CST-Post. Diastolic function: c Left
ventricular end-diastolic pressure (LVEDP) (mmHg) during the
30-min ischemia and 120-min reperfusion. d Percent variation of
ﬁrst derivative of LVP during diastole (dP/dtmin) with respect to
baseline level for each group, during the 30-min ischemia and
120-min reperfusion Time 0 correspond to the beginning of reper-
fusion. PostC post-conditioning, CST catestatin. ** P\0.01 with
respect to I/R (for further explanation see text)
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ischemia, increasing cell viability rate of about 65%. In this
study, the post-ischemic rat heart was perfused with a CST
concentration (75 nM), which is within the same range of
concentrations of the precursor CgA, detected in plasma of
patients suffering myocardial infarction (about 1 nM) or
CHF (about 10 nM) (Ceconi et al. 2002; Omland et al.
2003). It is also similar to the peptide concentration
(IC50 * 100 nM) which depresses myocardial inotropism
in perfused hearts (Angelone et al. 2008), and appears
slightly lower than the IC50 value for CST-induced inhi-
bition of the nicotinic cholinergic receptor-mediated cate-
cholamine release in bovine adrenal chromafﬁn cells
(Mahata et al. 1997).
Fig. 4 Cardiomyocytes
survival after simulated I/R:
representative experiment of a
simulated I/R experiment:
freshly isolated cardiomyocytes
adhered on glass bottom dishes
were placed under the confocal
microscope and processed with
the in vitro ischemia/reperfusion
protocol as indicated in Fig. 1b.
Cell viability was assessed by
monitoring the time course of
propidium iodide (PI) staining.
Confocal Image acquisitions for
each experimental condition
(Tyr, IB, or CST) were
performed at the times I, II, and
III indicated Fig. 1b. Cells
damaged by I/R are indicated by
white (pre-reperfusion) or black
(post-reperfusion) arrows (for
further explanation see text).
Bar graph summarizes the
viability rate in the control
protocol (Ctrl: 81.25%, 28 cells
from three different
experiments), in the I/R
protocol (IB: 64 cells from
seven experiments), and in the
catestatin protocol (IB ? CST:
45 cells from six experiments).
Viability rate was quantiﬁed as
the number of unstained cells at
the end of reperfusion (PostRep)
with respect to the number of
unstained cells at t = 0
(PreRep) (no cells PostRep/no
cells PreRep) 9 100. Results
are presented as mean ± SEM.
* P\0.05
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123Contracture limitation has been suggested as a very
good indicator of I/R injury (Penna et al. 2009c; Gelpi et al.
2002). In fact, both ischemic PostC and CST-Post mark-
edly limited contracture development during reperfusion.
Furthermore, CST was somewhat more protective than
ischemic PostC, as the improvement of systolic function
with CST-Post was greater than that observed with ische-
mic PostC. Since heart rate and ventricular volume were
kept constant, a role for both force–frequency relation-
ship and a Starling effect can be excluded. Therefore,
the improved systolic function is suggestive of a direct anti-
stunning effect by CST. Whether or not ischemic PostC
improves stunning is controversial (Couvreur et al. 2006;
Penna et al. 2009a, c). Many authors suggested that the
PostC maneuvers (intermittent ﬂow interruption) do not
abolish the stunning and that the improvement of global
cardiac function, if any, shouldbe due to anti-necrotic effect
(Couvreur et al. 2006; Penna et al. 2009a, c). Moreover,
increased cell viability does not necessarily correspond to
improved systolic function because cell can be viable but
stunned. Despite similar anti-infarcting effect by ischemic
PostC and CST-Post, we observed a better recovery of
systolic function with CST-Post. Accordingly, it is likely
that the limitation of post-ischemic contracture is reﬂected
in a CST-elicited increase in dP/dt and anti-stunning effect.
Limited contracture is likely due to a reduced calcium
overload resulting either from calcium extrusion and/or
from increased re-uptake by sarco/endoplasmic reticulum
Ca
2?-ATPase (SERCA). While the former may reduce
contractility, the latter tends to increase it. Of note, Ange-
lone et al. (2008) reported that, in the absence of ischemia,
CST negatively inﬂuences the inotropism. However, our
post-ischemic testing of CST in this study and our previous
study in normal heart (Angelone et al. 2008) are not directly
comparable. Being the aim of this study not mechanistically
oriented, the CST anti-contracture and anti-stunning effects
deserve further investigation.
It has been shown that several peptides such as brady-
kinin, opioids, and tumor necrosis factor (TNFa) are able to
induce post-conditioning-like cardioprotective effects (Bell
and Yellon 2003; Penna et al. 2008a, b; Lecour 2009).
These peptides, acting on their speciﬁc receptors, can
trigger both pharmacological pre- and post-conditioning
via pro-survival intrinsic signaling cascades, which include
in rodents the so called Reperfusion Injury Salvage Kinases
(RISK) and Survivor Activating Factor Enhancement
(SAFE) pathways (Heusch et al. 2008; Penna et al. 2008a, b;
Lecour 2009). Here, we show that like these peptides, CST
is also able to induce cardioprotection either if given during
the early reperfusion phase in isolated hearts, or if added
during a challenging ischemia in isolated cells. In ongoing
experiments, CST, given as a pre-conditioning agent,
reduced infarct size and post-ischemic contracture less than
CST-Post. Moreover, only CST-Post signiﬁcantly
improved post-ischemic recovery of developed LVP.
Therefore, CST seems more protective as PostC agent than
as a pre-conditioning mimetic.
Of note, in patients with CHF circulating CgA is
increased and is an independent predictive factor for
mortality (Ceconi et al. 2002). In particular, CgA correlates
with soluble TNF receptors (sTNF-Rs) (Corti et al. 2000).
The good correlation between CgA and sTNF-Rs and the
lack of correlation with neuroendocrine variables (Corti
et al. 2000), suggest that circulating CgA reﬂects systemic
inﬂammation much better than neuroendocrine activation
in CHF (Corti et al. 2000; Ceconi et al. 2002).
Apart from its interaction with nicotinic receptors
(Mahata et al. 1997, 2000, 2010), the mechanisms under-
lying the action of CST at the cardiac level remains to be
clariﬁed (Helle et al. 2007, 2010). It has been proposed that
CST may interact with the alpha subunit of Gi protein
(Helle et al. 2007; Helle 2010). Nevertheless, CST and its
analogue VS are able to activate a cascade similar to that
involved in cardioprotection when given before ischemia
(Cappello et al. 2007; Angelone et al. 2008). In particular,
it has been reported that VS cross-reacts with adenosine
receptors to induce protection (Cappello et al. 2007).
Since CST activates some elements of the RISK path-
way, including nitric oxide synthase, and may antagonize
adrenergic effects (Herrero et al. 2002; Angelone et al.
2008), we wondered whether CST may be cardioprotective
independently from the endothelial and anti-adrenergic
effects. In fact, it is well known that NO plays a cardio-
protective role (Penna et al. 2006; Cappello et al. 2007;
Heusch et al. 2008) and it has been demonstrated that
endothelium-derived NO mediates the VS-1-induced anti-
adrenergic effect in rat ventricular myocardium (Gallo et al.
2007; Cerra et al. 2008). Moreover, it has been suggested
that b1-adrenoreceptor stimulation may be detrimental in
the reperfusion phase, thus increasing infarct size (Feuer-
stein et al. 1998; Gao et al. 2000). Noteworthy, also in
human CHF, chronic heightened activation of the sympa-
thetic system and associated enhancement of catechol-
amine-induced signaling pathways have adverse prognostic
signiﬁcance and may accelerate the pathological processes
(Esler et al. 1997). In the heart, catecholamines are co-
stored and co-released with other neuropeptides and
humoral principles, in the heterogeneous population of
afferent, efferent, and interconnecting short neurons and
intracardiac ganglia, in the chromafﬁn cells, the endocardial
endothelium, the coronary vessels, and the connective cells
of the interstitium, as well as in the myocardiocytes them-
selves. The latter include the population of intrinsic cardiac
adrenergic cells identiﬁed in 1996 by Huang et al. (1996)i n
rodent and in human hearts. Accordingly, these intracardiac
converging adrenergic stimuli may signiﬁcantly augment
Cell Mol Neurobiol (2010) 30:1171–1179 1177
123the adrenergic activation of the heart under stressful con-
ditions. Therefore, since in the isolated rat heart excitatory
adrenergic cascades are likely to occur (Chahine et al.
1994), we argue that the observed cardioprotective effects
are, at least in part, related to the anti-adrenergic effect of
CST (Mahata et al. 1997; Herrero et al. 2002; Angelone
et al. 2008). However, since we observed a well evident
limitation of I/R injury also in the isolated cardiomyocytes,
we suggest that CST is able to attainsuch protection also via
a direct effect on cardiomyocytes, which is independent
from catecholamine presence in the extracellular milieu.
Furthermore, in reperfusion the protective effect is not
obligatorily endothelial-dependent. Our results, however,
do not rule out an additional role for the anti-adrenergic
and/or endothelium-dependent mechanisms in the in situ
heart. In fact, endothelium was required in the negative
inotropic effect of vasostatin (Gallo et al. 2007; Cerra et al.
2008). Yet, a higher CST concentration was required in the
heart (75 nM) with respect to cardiomyocytes (5 nM),
possibly because of hampered mass transfer of the peptide
to myocardial target trough the endothelium. Our study
does not allow to compare CST potency between isolated
cardiomyocytes and whole organ. Likely, on the isolated
heart, higher CST concentrations should be used for
reaching interstitial peptide levels comparable to the iso-
lated cardiomyocyte experimental conditions.
In conclusion, CST applied in the reperfusion is pro-
tective especially in terms of improvement of post-ische-
mic cardiac function. Since protection is observed in both
isolated heart and isolated cardiomyocytes, we suggest that
the protective effect is primarily due to a direct effect on
the myocardium and does not necessarily depend on the
antiadrenergic and/or endothelial effects of CST.
Conceivably, CST inﬂuence may be multifunctional,
being achieved not only via the baroceptor and sympa-
thoadrenal systems, but also via direct protective mech-
anisms on cardiomyocytes. Our study may provide
insights into the importance of the stimulus-secretion
coupling of CgA and its spatio-temporal processing as an
attempt of the cardiovascular system to protect itself
against I/R damages and associated patho-physiological
disturbances.
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